Mendus AB (publ) has a highly liquid capital structure, with cash and equivalents amounting to 130.16 million SEK, representing 17.6% of total assets. The company's liquidity position is further re…
Immuneering Corp maintains a strong liquidity position with $66.29 million in cash and equivalents, representing 75.4% of total assets, and no long-term debt, resulting in a debt-to-equity ratio of…
Kezar Life Sciences Inc has a strong liquidity position, with cash and equivalents amounting to $71.88 million, which is significantly higher than its total liabilities of $6.57 million, resulting…
Structure and Liquidity Novocure has a market capitalization of $2.08 billion and a price-to-book ratio of 6.1, indicating a premium valuation relative to its book value. The company's liquidity po…
PepGen Inc operates with a strong liquidity position, as evidenced by a current ratio of 7.45 and cash and equivalents of $66.09 million, which significantly exceeds its total liabilities of $38.47…
Pharma Mar maintains a conservative capital structure with a debt-to-equity ratio of 0.2, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium ri…
P3 Health Partners Inc operates with a negative equity position of $155.23 million and a total liabilities-to-equity ratio of -1.76, indicating a highly leveraged capital structure. The company's l…
The company's capital structure shows a debt-to-equity ratio of 0.42, indicating a relatively conservative leverage position. However, the negative net cash position after subtracting total debt ra…
Siegfried's capital structure is relatively balanced, with a debt-to-equity ratio of 0.51, indicating moderate leverage. The company maintains a current ratio of 2.0, suggesting it has sufficient s…
ARS Pharmaceuticals Inc operates with a market capitalization of $817.24 million and a price-to-book ratio of 7.15, indicating a premium valuation relative to its book value. The company's liquidit…
Veru Inc has a market capitalization of $33.55 million and a price-to-book ratio of 0.74, indicating that the company is trading at a discount to its book value. The company's liquidity position is…
VolitionRX operates with a negative equity position of -$15.6 million and a total asset base of $19.4 million, indicating a capital structure heavily reliant on liabilities. The company's liquidity…
Vertex Pharmaceuticals Inc maintains a robust capital structure with a current ratio of 3.5, indicating strong short-term liquidity. The company's liquidity position is further supported by $9.16 b…
XBiotech operates with a strong liquidity position, as evidenced by its cash and equivalents of $125.55 million, which significantly exceeds its total liabilities of $9.73 million, resulting in a c…
Zydus Lifesciences Ltd maintains a strong liquidity position, with a current ratio of 1.89, indicating that the company has sufficient current assets to cover its current liabilities. The company's…
Zymeworks maintains a strong liquidity position with a current ratio of 5.88, indicating that its current assets significantly exceed its current liabilities. The company holds $32.19 million in ca…
Dong-E-E-Jiao maintains a strong liquidity position, with a current ratio of 4.65, indicating the company can easily cover its short-term liabilities with its short-term assets. The company has a n…
The company's capital structure is characterized by a strong equity base, with total equity of CNY 5.18 billion and no long-term debt, resulting in a debt-to-equity ratio of 0.0. Liquidity is robus…
Jinxin Fertility Group Ltd has a market price of 2.23 CNY and a market capitalization of 6.03 billion CNY, with a price-to-book ratio of 0.66 and a price-to-tangible-book ratio of 0.66. The company…
Porton Pharma Solutions Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.28, indicating a relatively low reliance on debt financing. The company's liquidity position…
Jafron Biomedical Co Ltd maintains a strong liquidity position with a current ratio of 5.81, indicating the company can easily cover its short-term liabilities with its current assets. However, the…
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.03 and a current ratio of 2.98, indicating strong short-term liquidity coverage. Total equity stands at $499.…
Aligos Therapeutics Inc maintains a strong liquidity position, with $45.08 million in cash and equivalents, and a current ratio of 4.23, indicating a robust ability to meet short-term obligations.…
Amarin operates with a strong liquidity position, as evidenced by $134.66 million in cash and equivalents and a current ratio of 3.34, indicating the company can easily cover its short-term liabili…
American Well operates with a highly liquid capital structure, as evidenced by $276.9 million in cash and equivalents, which significantly exceeds its total liabilities of $143.9 million, resulting…
The company maintains a strong liquidity position, with a current ratio of 10.61, indicating that it has significantly more current assets than current liabilities. Its cash and equivalents amount…
Atossa Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $79.53 million, representing 92.7% of total assets. The company has no long-term debt and a cur…
BioCryst Pharmaceuticals maintains a negative equity position of -119.2 million USD against total liabilities of 633.3 million USD and total assets of 514.2 million USD. The company holds 89.7 mill…
BICO Group AB has a liquidity position that is currently medium, with a current ratio of 2.86, indicating the company can cover its short-term liabilities with its short-term assets. However, the c…
Boule Diagnostics has a market price of 3.52 SEK and a market capitalization of 136,692,526.08 SEK, with a price-to-book ratio of 0.28 and a price-to-tangible-book ratio of 0.28, indicating a signi…
Cellectis operates with a market capitalization of $294.42 million and a price-to-book ratio of 3.88, indicating a premium valuation relative to its book value. The company's liquidity position is…
Elutia's capital structure is highly leveraged, with total liabilities of $85.66 million and total equity of -$50.30 million, indicating a negative net worth. The company's liquidity position is we…
Forian Inc. has a market capitalization of $63.42 million and a price-to-book ratio of 2.13, indicating a premium valuation relative to its book value. The company's liquidity position is strong, w…
Fractyl Health Inc operates with a strong liquidity position, as evidenced by its cash and equivalents of $121.44 million, which significantly exceeds its total liabilities of $79.34 million, resul…
Werewolf Therapeutics Inc operates with a highly liquid capital structure, as evidenced by a current ratio of 12.13, indicating strong short-term liquidity. The company holds $135.3 million in cash…
Inmode Ltd maintains a pristine capital structure with zero debt, evidenced by a debt-to-equity ratio of 0.0. The balance sheet is heavily weighted toward liquidity, holding $302.5 million in cash…
LifeMD operates with a market capitalization of $194.44 million and a price-to-earnings ratio of 13.55, indicating a moderate valuation relative to earnings. The company's liquidity position is cha…
Mentice operates with a market capitalization of 413.45 million SEK and a price-to-earnings ratio of 23.97, indicating a relatively high valuation compared to earnings. The company's price-to-book…
Marker Therapeutics operates with a strong liquidity position, as evidenced by a current ratio of 6.12 and cash and equivalents of $11.32 million. The company has no long-term debt, and its debt-to…
Nektar Therapeutics operates with a capital structure that is highly leveraged to equity, as evidenced by a price-to-book ratio of 25.21 and a debt-to-equity ratio of 0.7. The company's liquidity p…
Nuvalent maintains a strong liquidity position with a current ratio of 15.27, indicating that its current assets significantly exceed its current liabilities. The company holds $261.75 million in c…
NextCure maintains a strong liquidity position with a current ratio of 10.7, indicating that its current assets significantly exceed its current liabilities. The company holds $18.36 million in cas…
Onkure Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $59.05 million, representing 95.2% of total assets. The company has no long-term debt and a cur…
Q32 Bio Inc maintains a strong liquidity position with $115.5 million in cash and equivalents, which significantly exceeds its total liabilities of $103.6 million, resulting in a current ratio of 4…
Rainbow Children's Medicare Ltd maintains a strong liquidity position, with a current ratio of 5.46, indicating the company can easily cover its short-term liabilities with its short-term assets. H…
Rede D'Or Sao Luiz SA has a debt-to-equity ratio of 2.58, indicating a significant reliance on debt financing, which is higher than the typical industry median for healthcare facilities. The compan…
Rein Therapeutics Inc has a market capitalization of $88.18 million and a price-to-book ratio of 0.97, indicating that the company is trading at a slight discount to its book value. The company has…
10X Genomics maintains a strong liquidity position with $474 million in cash and equivalents, representing 45.5% of total assets, and a current ratio of 4.46, well above the industry median of 1.8.…
vTv Therapeutics maintains a strong liquidity position, with $52.26 million in cash and equivalents, and a current ratio of 6.04, indicating a robust ability to meet short-term obligations. The com…
The company maintains a highly leveraged capital structure with a debt-to-equity ratio of 16.1, indicating significant reliance on debt financing relative to equity. Total liabilities stand at $369…
Exagen Inc operates with a liquidity position that is relatively strong, as evidenced by its cash and equivalents of $27.27 million, which significantly exceeds its total liabilities of $30.82 mill…
Samil Pharmaceutical's capital structure is highly leveraged, with a debt-to-equity ratio of 1.0, indicating that the company's total liabilities are equal to its total equity. The company's liquid…
The company maintains a strong capital structure with a debt-to-equity ratio of 0.03, indicating minimal leverage and a conservative approach to financing. However, its liquidity position is mixed,…
Genscript Biotech Corp has a capital structure characterized by a low debt-to-equity ratio of 0.07, indicating a conservative leverage position. The company's liquidity is assessed as medium, with…
The company's capital structure is characterized by a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…
HK Inno.N Corp maintains a debt-to-equity ratio of 0.39, indicating a relatively conservative capital structure with a strong equity base. The company's liquidity position is characterized as mediu…
Il Dong Pharmaceutical has a market price of 22,300 KRW and a market capitalization of 702.63 billion KRW, with a price-to-book ratio of 4.29 and a price-to-tangible-book ratio of 4.29. The company…
Shanghai Henlius Biotech Inc maintains a capital structure characterized by significant leverage and tight liquidity metrics. The company reports total assets of CNY 12.36 billion against total lia…
Edan Instruments Inc maintains a strong liquidity position, with a current ratio of 4.67, indicating the company can easily cover its short-term liabilities with its current assets. The company's l…
Yantai Zhenghai Bio-Tech Co Ltd maintains a strong liquidity position, with a current ratio of 8.6 and no long-term debt, indicating a robust balance sheet and minimal leverage risk. The company's…
SK Bioscience's capital structure shows a debt-to-equity ratio of 0.26, indicating a relatively conservative leverage position. However, the company's liquidity is assessed as medium, with a curren…
The company's capital structure is characterized by a debt-to-equity ratio of 0.8, indicating a moderate reliance on debt financing. Despite holding significant cash and equivalents of KRW 16,267,8…
TTY Biopharm maintains a strong liquidity position, with a current ratio of 2.28 and cash and equivalents of TWD 1.26 billion, which supports its operational flexibility. The company's price-to-boo…
The company maintains a strong liquidity position, with a current ratio of 27.17, indicating a significant excess of current assets over current liabilities. Its cash and equivalents amount to 1,52…
Astellas Pharma maintains a conservative capital structure with a debt-to-equity ratio of 0.37 and a current ratio of 1.17. The balance sheet shows total assets of JPY 3.57 trillion against total l…
JCR Pharmaceuticals has a market capitalization of ¥60.02 billion and a price-to-book ratio of 1.28, indicating a moderate premium over its book value. The company's liquidity position is character…
PeptiDream maintains a strong liquidity position, with cash and equivalents amounting to ¥28.68 billion, which is significantly higher than its total liabilities of ¥25.50 billion, resulting in a c…
Onconic Therapeutics Inc exhibits a strong capital structure with a current ratio of 17.62, indicating a high level of liquidity and the ability to meet short-term obligations comfortably. The comp…
The company maintains a market price of 2167.0 JPY, with a market capitalization of 52,886,025,060.0 JPY, indicating a moderate valuation relative to its equity and tangible book value. The price-t…
Actuate Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $13.16 million, which is significantly higher than its total liabilities of $6.11 million, res…
Annexin Pharmaceuticals maintains a strong liquidity position, with a current ratio of 7.39, indicating that the company has sufficient current assets to cover its current liabilities multiple time…
BION.NS has a liquidity position that is characterized by a current ratio of 1.14, indicating that the company has slightly more current assets than current liabilities. However, the company's cash…
BioLine RX operates with a market capitalization of $13.32 million and a price-to-book ratio of 1.02, indicating a valuation close to its book value. The company's liquidity position is characteriz…
Cabaletta Bio Inc maintains a strong liquidity position, with cash and equivalents amounting to $178.6 million, representing 82% of total assets. The company has no long-term debt and a current rat…
Coherus Oncology Inc operates with a market capitalization of $275.28 million and a price-to-earnings ratio of 1.64, indicating a relatively low valuation compared to earnings. The company's liquid…
Clene Inc has a market capitalization of $83.04 million and a price-to-book ratio of 19.47, indicating a high valuation relative to its book value. The company's liquidity position is characterized…
CNS Pharmaceuticals maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $8.62 million against total liabil…
Cocrystal Pharma Inc maintains a strong liquidity position, with a current ratio of 10.3 and cash and equivalents amounting to $21.84 million, which significantly exceeds its total liabilities of $…
CRVO maintains a strong liquidity position with $6.37 million in cash and equivalents, representing 79.7% of total assets, and a current ratio of 2.99, indicating robust short-term financial health…
Cervus Biotech maintains a strong liquidity position, with a current ratio of 9.66, indicating that its current assets significantly exceed its current liabilities. The company's free cash flow of…
Cadrenal Therapeutics Inc operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0 and a current ratio of 3.72, indicating strong short-term l…
Dare Bioscience Inc operates with a negative equity position of -$10.999 million and a cash balance of $3.631 million, indicating a liquidity risk despite having no dilution pressure in the near te…
The company's capital structure is characterized by a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…
ECOR.BO maintains a strong liquidity position with a current ratio of 4.52 and a low debt-to-equity ratio of 0.05, indicating minimal reliance on debt financing and a robust balance sheet. The comp…
EPI.AX has a negative equity position of -37,593,610 AUD and a debt-to-equity ratio of -1.5, indicating a highly leveraged capital structure. The company's liquidity is rated as medium, with a curr…
Equillium Inc has a market capitalization of $163.76 million and a price-to-book ratio of 5.73, indicating that the market is valuing the company at a premium to its book value. The company's liqui…
Fate Therapeutics Inc operates with a market capitalization of $220.94 million and a price-to-book ratio of 0.56, indicating a significant discount to its book value. The company holds $36.92 milli…
GKOS.K has a market price of $134.92, resulting in a market capitalization of $7.92 billion. The company's price-to-book ratio is 12.08, and its price-to-tangible-book ratio is also 12.08, indicati…
Gossamer Bio operates with a high debt-to-equity ratio of 7.72, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is characterized by a current rati…
Grace Therapeutics maintains a strong liquidity position, with a current ratio of 11.77, indicating that its current assets significantly exceed its current liabilities. The company holds $21.3 mil…
Halo Therapeutics maintains a capital structure characterized by a high debt-to-equity ratio of 43.89, indicating a significant reliance on debt financing relative to equity. The company's liquidit…
HLS.AX exhibits a capital structure with a debt-to-equity ratio of 1.55, indicating a significant reliance on debt financing. The company's liquidity position is characterized by a current ratio of…
Heidelberg Pharma maintains a strong liquidity position, with cash and equivalents amounting to €42.6 million, which is significantly higher than its total liabilities of €30.8 million, resulting i…
ImageneBio Inc has a strong liquidity position, with a current ratio of 18.22, indicating that the company has significantly more current assets than current liabilities. The company holds $44.27 m…
Intensity Therapeutics Inc maintains a strong liquidity position, with a current ratio of 2.32 and cash and equivalents of $3.24 million, indicating the company has sufficient short-term assets to…
The company maintains a strong liquidity position, with a current ratio of 7.16 and cash and equivalents amounting to 128.5 million SEK, which significantly exceeds its total liabilities of 19.1 mi…
The company maintains a strong liquidity position, with a current ratio of 5.35, indicating that it has more than five times the current assets to cover its current liabilities. Its cash and equiva…
Lytix Biopharma AS has a strong liquidity position, with a current ratio of 3.91, indicating that the company holds nearly four times more current assets than current liabilities. The company's cas…
Marathon Pharmaceuticals has a liquidity position that is marginally constrained, with a current ratio of 0.83, indicating that its current liabilities exceed its current assets. The company's cash…
MDX.V's capital structure is highly leveraged, with total liabilities of CAD 940.8 million and total equity of CAD -852.4 million, resulting in a negative debt-to-equity ratio of -0.82. The company…
medmix AG's capital structure is characterized by a debt-to-equity ratio of 0.78, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a cu…
Milestone Pharmaceuticals Inc operates with a high liquidity position, as evidenced by a current ratio of 8.01 and cash and equivalents of $73.05 million, which significantly exceeds its total liab…
Milestone Scientific Inc operates with a market capitalization of $27.41 million and a price-to-book ratio of 9.75, indicating a premium valuation relative to its book value. The company's liquidit…
MiniMed Group Inc has a market capitalization of $3.39 billion and a price-to-book ratio of 1.02, indicating that the market values the company at a slight premium to its book value. The company's…
Monopar Therapeutics Inc operates with a highly liquid capital structure, as evidenced by its cash and equivalents of $6.12 million, which constitutes 85.2% of its total assets. The company has no…
Neuland Laboratories Ltd maintains a strong liquidity position with a current ratio of 2.45, indicating the company can cover its short-term liabilities more than twice over with its current assets…
Neurogene Inc has a strong liquidity position, with a current ratio of 16.56, indicating that the company has significantly more current assets than current liabilities. The company holds $103.85 m…
Northwest Biotherapeutics operates with a capital structure that is highly leveraged and liquidity-constrained. The company has negative total equity of $47.57 million and a debt-to-equity ratio of…
OraSure Technologies Inc exhibits a strong liquidity position, with $199.28 million in cash and equivalents and a current ratio of 6.58, indicating a robust ability to meet short-term obligations.…
Owlet Inc operates with a negative equity position of -$20.83 million and a total debt of $11.85 million, indicating a leveraged capital structure. The company's liquidity position is constrained,…
The company's capital structure is characterized by a high proportion of equity, with total equity of AUD 21.18 million compared to total liabilities of AUD 3.39 million, resulting in a debt-to-equ…
Pfizer maintains a capital structure with a debt-to-equity ratio of 0.75, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1…
BiomX Inc operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company's liquidity position is characterized by a cur…
Pliant Therapeutics Inc has a market capitalization of $72.13 million and a price-to-book ratio of 0.16, indicating a significant discount to its book value. The company's liquidity position is str…
Pulse Biosciences maintains a pristine balance sheet with $80.7 million in cash and equivalents against total liabilities of $13.9 million, resulting in a debt-to-equity ratio of 0.0. The company h…
The company's capital structure is characterized by a high price-to-book ratio of 7.62, indicating that the market is valuing the company significantly above its book value. This is supported by a…
Quanterix operates with a highly liquid capital structure, holding $29.3 million in cash and equivalents against total liabilities of $72.1 million, resulting in a current ratio of 10.07. The compa…
Rocket Pharmaceuticals has a market capitalization of $326.28 million and a price-to-book ratio of 1.18, indicating that the market values the company slightly above its book value. The company's l…
Scienture Holdings Inc has a market capitalization of $16.7 million and a price-to-earnings ratio of 0.79, indicating a relatively low valuation compared to earnings. The company's price-to-book ra…
Swedencare's capital structure is characterized by a market cap of 4.24 billion SEK and a price-to-book ratio of 0.64, indicating that the company's market value is below its book value. The compan…
The company maintains a strong liquidity position with a current ratio of 3.86, indicating that it has sufficient current assets to cover its current liabilities. The company's liquidity is further…
SMSMED.CO's capital structure is characterized by a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a cu…
SOPHiA GENETICS operates with a market price of $4.74 and a market capitalization of $339.71 million, indicating a relatively small capitalization for its industry. The company's price-to-book rati…
Sprint Bioscience operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company maintains a current ratio of 1.71, ind…
TScan Therapeutics Inc maintains a strong liquidity position, with $152.4 million in cash and equivalents, representing 66.6% of total assets. The company's price-to-book ratio of 0.5 and price-to-…
Telomir Pharmaceuticals Inc operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.00 and no long-term debt. The company's liquidity position…
The company's capital structure is characterized by a debt-to-equity ratio of 0.14, indicating a relatively low reliance on debt financing. However, its liquidity position is assessed as medium, wi…
Terrascend Corp maintains a capital structure characterized by significant leverage, with total liabilities of $459.9 million against total equity of $97.5 million, resulting in a debt-to-equity ra…
Xbrane Biopharma AB maintains a strong liquidity position, with a current ratio of 7.12, indicating that the company has sufficient current assets to cover its current liabilities multiple times ov…
Xspray Pharma operates with a capital structure that includes total assets of SEK 736.1 million and total liabilities of SEK 67.9 million, resulting in a debt-to-equity ratio of 0.05. The company's…
Zevra Therapeutics maintains a conservative capital structure with total equity of $154.7 million and long-term debt of $61.9 million, resulting in a debt-to-equity ratio of 0.4. The company holds…
Yifan Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.29, indicating that it can cover its short-term liabilities with its short-term assets. Howev…
Samjin Pharmaceutical maintains a conservative capital structure with a debt-to-equity ratio of 0.47, indicating a relatively low reliance on debt financing. The company's liquidity position is cha…
The company maintains a strong liquidity position, with a current ratio of 3.64 and cash and equivalents of KRW 43,957,795,930, indicating robust short-term financial flexibility. The price-to-book…
China Medical System Holdings Ltd maintains a strong liquidity position, with a current ratio of 6.33, indicating a robust ability to meet short-term obligations. The company's price-to-book ratio…
ScinoPharm maintains a strong liquidity position, with a current ratio of 7.74 and cash and equivalents amounting to TWD 2,993.5 million, which is significantly higher than the typical liquidity re…
The company's capital structure is characterized by a very low debt-to-equity ratio of 0.0, indicating a nearly debt-free balance sheet. It holds substantial cash and equivalents of $31.7 million,…
The company maintains a strong liquidity position, with a current ratio of 12.84, indicating a high ability to meet short-term obligations. However, its free cash flow is negative at -316.71 millio…
Autek China Inc maintains a strong liquidity position with a current ratio of 5.77, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score suggests a medium l…
Imeik Technology Development Co Ltd maintains a strong liquidity position with a current ratio of 6.41, indicating a robust ability to meet short-term obligations. However, the company's free cash…
Vuno Inc operates with a capital structure that includes a debt-to-equity ratio of 0.21, indicating a relatively conservative leverage position. The company holds cash and equivalents of KRW 5,554,…
OBI Pharma Inc has a capital structure characterized by a debt-to-equity ratio of 0.27, indicating a relatively low reliance on debt financing. The company holds cash and equivalents of 470 million…
Topchoice Medical Co Inc maintains a strong capital structure with a debt-to-equity ratio of 0.26, indicating a relatively low reliance on debt financing. The company's liquidity position is charac…
ACLX.O has a strong liquidity position, with $80.26 million in cash and equivalents and a current ratio of 4.44, indicating the company is well-positioned to meet its short-term obligations. The co…
Anixa Biosciences Inc has a market capitalization of $96.9 million and a price-to-book ratio of 4.1, indicating a premium valuation relative to its book value. The company's liquidity position is s…
Bicycle Therapeutics has a market capitalization of $326.02 million and a price-to-book ratio of 0.53, indicating that the company is trading at a discount relative to its book value. The company's…
Structure and Liquidity BioInvent has a market capitalization of 2.81 billion SEK and a price-to-book ratio of 2.56, indicating a premium valuation relative to its book value. The company's liquidi…
BVC.L has a liquidity position characterized by a current ratio of 1.85, indicating the company can cover its short-term liabilities with its short-term assets. The company holds cash and equivalen…
Beyondspring Inc operates with a negative equity position of $32.16 million and a cash and equivalents balance of $7.79 million, indicating a liquidity position that is constrained by its negative…
Vi sender deg én e-post når Handelsavisen lanseres. Ingen spam, ingen annen bruk.
Ved å registrere deg samtykker du til å motta ett enkelt varsel fra Handelsavisen på lanseringsdagen.